Moleculin Biotech (MBRX) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Moleculin Biotech (NASDAQ: MBRX) in the last few weeks:

• 11/29/2024 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/21/2024 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/13/2024 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/12/2024 – Moleculin Biotech had its price target lowered by analysts at Maxim Group from $20.00 to $8.00. They now have a “buy” rating on the stock.
• 11/5/2024 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/28/2024 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/20/2024 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/12/2024 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/4/2024 – Moleculin Biotech is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Moleculin Biotech Price Performance

MBRX stock traded down $0.16 during trading on Tuesday, reaching $2.53. 10,189 shares of the stock were exchanged, compared to its average volume of 33,064. The business has a 50 day moving average price of $2.57 and a 200-day moving average price of $3.11. Moleculin Biotech, Inc. has a 1 year low of $2.12 and a 1 year high of $15.75.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC boosted its holdings in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,000 shares of the company’s stock after purchasing an additional 7,505 shares during the quarter. Armistice Capital LLC owned about 6.75% of Moleculin Biotech worth $549,000 at the end of the most recent quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.